Harry W Lampiris

Summary

Country: USA

Publications

  1. ncbi Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
    Harry W Lampiris
    University of California, San Francisco, CA, USA
    Expert Rev Anti Infect Ther 10:13-20. 2012

Detail Information

Publications1

  1. ncbi Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
    Harry W Lampiris
    University of California, San Francisco, CA, USA
    Expert Rev Anti Infect Ther 10:13-20. 2012
    ..The in vitro activity, pharmacokinetic and pharmacodynamic properties, results of Phase I-III clinical trials, resistance profile and drug-drug interactions of EVG will be reviewed in this article...